CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Value
CRISPR Therapeutics AG operates as a gene editing company. [ Read More ]
The intrinsic value of one CRSP stock under the Base Case scenario is 162.33 USD. Compared to the current market price of 53.91 USD, CRISPR Therapeutics AG is Undervalued by 67%.
Valuation Backtest
CRISPR Therapeutics AG
Run backtest to discover the historical profit from buying and selling CRSP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CRISPR Therapeutics AG
Current Assets | 1.9B |
Cash & Short-Term Investments | 1.7B |
Receivables | 200m |
Other Current Assets | 14.4m |
Non-Current Assets | 321.5m |
Long-Term Investments | 2m |
PP&E | 305.9m |
Intangibles | 16k |
Other Non-Current Assets | 13.6m |
Current Liabilities | 108.8m |
Accounts Payable | 38.1m |
Accrued Liabilities | 61m |
Other Current Liabilities | 9.7m |
Non-Current Liabilities | 238m |
Other Non-Current Liabilities | 238m |
Earnings Waterfall
CRISPR Therapeutics AG
Revenue
|
371.2m
USD
|
Operating Expenses
|
-593.7m
USD
|
Operating Income
|
-222.5m
USD
|
Other Expenses
|
68.9m
USD
|
Net Income
|
-153.6m
USD
|
Free Cash Flow Analysis
CRISPR Therapeutics AG
CRSP Profitability Score
Profitability Due Diligence
CRISPR Therapeutics AG's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
CRISPR Therapeutics AG's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
CRSP Solvency Score
Solvency Due Diligence
CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRSP Price Targets Summary
CRISPR Therapeutics AG
According to Wall Street analysts, the average 1-year price target for CRSP is 87.55 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.
Ownership
CRSP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRSP Price
CRISPR Therapeutics AG
Average Annual Return | 28.88% |
Standard Deviation of Annual Returns | 102.29% |
Max Drawdown | -82% |
Market Capitalization | 4.3B USD |
Shares Outstanding | 80 276 000 |
Percentage of Shares Shorted | 18.63% |
CRSP News
Last Important Events
CRISPR Therapeutics AG
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
CRISPR Therapeutics AG
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CRISPR Therapeutics AG operates as a gene editing company. The company is headquartered in Zug, Zug and currently employs 473 full-time employees. The company focuses on the development of transformative gene-based medicines for serious diseases. The firm develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The firm has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The firm has business operations in London and the United Kingdom, as well as research and development operations in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one CRSP stock under the Base Case scenario is 162.33 USD.
Compared to the current market price of 53.91 USD, CRISPR Therapeutics AG is Undervalued by 67%.